Trial Profile
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 31 Oct 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.
- 31 Oct 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
- 02 Aug 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.